Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Collaboration › Details

Bluebird Bio–Goldman Sachs: investor conference, 201906 supply service Bluebird Bio at Goldman Sachs Annual Healthcare Conference


Period Period 2019-06-11
Region Region California (federal state)
  Country United States (USA)
Organisations Partner, 1st Bluebird Bio Inc. (Nasdaq: BLUE)
  Group Bluebird Bio (Group)
  Partner, 2nd Goldman Sachs & Co. LLC
  Group Goldman Sachs (Group)
Products Product Goldman Sachs Annual Global Healthcare Conference 2019 Rancho Palos Verdes, CA
  Product 2 gene therapy

Bluebird Bio, Inc.. (5/31/19). "Press Release: Bluebird Bio Announces Investor Events in June". Cambridge, MA.

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company will hold a conference call to discuss data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 14 at 8:00 am ET.

In addition, members of the management team will present at the following upcoming investor conferences:

> Jefferies 2019 Healthcare Conference, Tuesday, June 4, at 11:30 am ET at The Grand Hyatt, New York, NY

> Goldman Sachs 40th Annual Healthcare Conference, Tuesday, June 11 at 10:00 am PT at the Terranea Resort, Rancho Palos Verdes, CA

To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent ß-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of, and anticipated development and commercialization plans for, the Company’s product candidates. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials of our product candidates will not continue or be repeated in our ongoing or planned clinical trials; risks that the current or planned clinical trials of our product candidates will be insufficient to support future regulatory submissions or to support marketing approval in the U.S. and EU; and the risk that our product candidates will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Elizabeth Pingpank, (617) 914-8736


Jenn Snyder, (617) 448-0281

Record changed: 2019-06-01


Picture [LSA] – The Business Web Portal 650x89px

More documents for Bluebird Bio (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 iito 650x80px

» top